Swiss-based pharma company buying spark as rivals move aggressively into gene therapy
Top candidates for a share sale include Swiss firms AC Immune and Molecular Partners
Dicerna Pharmaceuticals a focal point of concern as it has yet to enter clinical trials and refused to impose share sale block on major shareholders
YOU MAY ALSO LIKE...
How does a post-Brexit world shape the identity and relationship of these islands
Inquests into the nightclub fire that led to the deaths of 48 people
Weddings, Births, Deaths and other family notices